Mycoplasma hyorhinis-encoded purine nucleoside phosphorylase: Kinetic properties and its effect on the cytostatic potential of purine-based anticancer drugs

Molecular Pharmacology

Volumn 84, Issue 6, 2013, Pages 865-875

  Voorde, Johan Vande ^a   Liekens, Sandra ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 DEOXY 2 FLUORO ADENOSINE; 2' DEOXY 2 FLUOROADENOSINE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; 6 METHYLPURINE; 6 METHYLPURINE 2' DEOXYRIBOSIDE; 8 AMINOGUANOSINE; ADENINE NUCLEOTIDE; CLADRIBINE; CLOFARABINE; DEOXYADENOSINE DERIVATIVE; FLUDARABINE; HYPOXANTHINE; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; METHYL( TALO) F ADO; PURINE NUCLEOSIDE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; THIOGUANOSINE; TIOGUANINE; TUBERCIDIN; UNCLASSIFIED DRUG; VIDARABINE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOSTASIS; DRUG EFFICACY; DRUG PURIFICATION; DRUG STABILITY; ENZYME SPECIFICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LYMPHATIC LEUKEMIA; MYCOPLASMA HYORHINIS; MYCOPLASMOSIS; PH; PRIORITY JOURNAL; PROKARYOTE; RNA SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLADRIBINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KINETICS; MYCOPLASMA HYORHINIS; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84888861820     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088625     Document Type: Article

References (53)

1. Acs G, Reich E, and Mori M (1964) Biological and biochemical properties of the analogue antibiotic tubercidin. Proc Natl Acad Sci USA 52:493-501.
2. Apostolou P, Tsantsaridou A, Papasotiriou I, Toloudi M, Chatziioannou M, and Giamouzis G (2011) Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothorac Surg 6:137-141.
3. Ardiani A, Johnson AJ, Ruan H, Sanchez-Bonilla M, Serve K, and Black ME (2012) Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy. Curr Gene Ther 12:77-91.
4. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, and Kantarjian H et al. (2010) Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116:886-892.
5. Barykova YA, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, Rakovskaya IV, Baker PS, Shyshynova I, and Stephenson AJ et al. (2011) Association of Mycoplasma hominis infection with prostate cancer. Oncotarget 2: 289-297.
6. Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA, 3rd, and Sorscher EJ et al. (2003) Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem Biol 10:1173-1181.
7. Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-956.
8. Bontemps F, Delacauw A, Cardoen S, Van Den Neste E, and Van Den Berghe G (2000) Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2′-deoxyadenosine. Biochem Pharmacol 59:1237-1243.
9. Bronckaers A, Balzarini J, and Liekens S (2008) The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. Biochem Pharmacol 76:188-197.
10. Bzowska A and Kazimierczuk Z (1995) 2-Chloro-2′-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase. Eur J Biochem 233:886-890.
11. Bzowska A, Kulikowska E, and Shugar D (2000) Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 88:349-425.
12. Chan PJ, Seraj IM, Kalugdan TH, and King A (1996) Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 63:258-260.
13. Chodosh LA, Fire A, Samuels M, and Sharp PA (1989) 5,6-Dichloro-1-beta-D- ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. J Biol Chem 264:2250-2257.
14. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, and Walley RJ et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-1077.
15. Clayton TA, Baker D, Lindon JC, Everett JR, and Nicholson JK (2009) Pharmaco-metabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106:14728-14733.
16. Cummins J and Tangney M (2013) Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agent Cancer 8:11-18.
17. Drew ME, Morris JC, Wang Z, Wells L, Sanchez M, Landfear SM, and Englund PT (2003) The adenosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library. J Biol Chem 278:46596-46600.
18. Erturhan SM, Bayrak O, Pehlivan S, Ozgul H, Seckiner I, Sever T, and Karakök M (2013) Can mycoplasma contribute to formation of prostate cancer? Int Urol Nephrol 45:33-38.
19. Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, and Tyler PC (2003) Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem 46:5271-5276.
20. Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, and Feliu J (2012) The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs 72:1057-1073.
21. Galmarini CM, Mackey JR, and Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415-424.
22. Gandhi V and Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93-103.
23. Gordon RK, Ginalski K, Rudnicki WR, Rychlewski L, Pankaskie MC, Bujnicki JM, and Chiang PK (2003) Anti-HIV-1 activity of 3-deaza-adenosine analogs: inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem 270:3507-3517.
24. Hijiya N, Barry E, and Arceci RJ (2012) Clofarabine in pediatric acute leukemia: current findings and issues. Pediatr Blood Cancer 59:417-422.
25. Huang S, Li JY, Wu J, Meng L, and Shou CC (2001) Mycoplasma infections and different human carcinomas. World J Gastroenterol 7:266-269.
26. Kazmers IS, Mitchell BS, Dadonna PE, Wotring LL, Townsend LB, and Kelley WN (1981) Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. Science 214:1137-1139.
27. Kidder M, Chan PJ, Seraj IM, Patton WC, and King A (1998) Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA. Gynecol Oncol 71:254-257.
28. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Pérez-Pérez MJ, and Balzarini J (2002) Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett 510:83-88.
29. Liekens S, Bronckaers A, and Balzarini J (2009) Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes. Lancet Oncol 10:628-635.
30. Liliemark J (1997) The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 32:120-131.
31. Liu W, Fang L, Li S, Li Q, Zhou Z, Feng Z, Luo R, Shao G, Wang L, and Chen H et al. (2010) Complete genome sequence of Mycoplasma hyorhinis strain HUB-1. J Bacteriol 192:5844-5845.
32. Mager DL (2006) Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 4:14-31.
33. McGarrity GJ and Carson DA (1982) Adenosine phosphorylase-mediated nucleoside toxicity. Application towards the detection of mycoplasmal infection in mammalian cell cultures. Exp Cell Res 139:199-205.
34. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, and Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281.
35. Nicholson JK, Holmes E, and Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3:431-438.
36. Parker WB (2009) Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 109:2880-2893.
37. Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AE, Silamkoti AV, Fowler AT, Waud WR, and Secrist JA, 3rd (2005) Design and evaluation of 5′-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucleosides Nucleotides Nucleic Acids 24:387-392.
38. Parker WB, Allan PW, Hassan AE, Secrist JA, 3rd, Sorscher EJ, and Waud WR (2003) Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 10:23-29.
39. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, and Bennett LL, Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55:1673-1681.
40. Parker WB, King SA, Allan PW, Bennett LL, Jr, Secrist JA, 3rd, Montgomery JA, Gilbert KS, Waud WR, Wells AH, and Gillespie GY, et al. (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 8:1637-1644.
41. Pavan-Langston D and Buchanan R (1976) Vidarabine therapy of simple and IDU-complicated herpetic keratitis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 81:813-825.
42. Pehlivan M, Itirli G, Onay H, Bulut H, Koyuncuoglu M, and Pehlivan S (2004) Does Mycoplasma sp. play role in small cell lung cancer? Lung Cancer 45:129-130.
43. Pehlivan M, Pehlivan S, Onay H, Koyuncuoglu M, and Kirkali Z (2005) Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma? Urology 65:411-414.
44. Pugmire MJ and Ealick SE (2002) Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 361:1-25.
45. Razin S, Yogev D, and Naot Y (1998) Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62:1094-1156.
46. Schramm VL (2013) Transition States, analogues, and drug development. ACS Chem Biol 8:71-81.
47. Sorscher EJ, Hong JS, Allan PW, Waud WR, and Parker WB (2012) In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol 70:321-329.
48. Temmink OH, Emura T, de Bruin M, Fukushima M, and Peters GJ (2007) Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 98:779-789.
49. Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, and Rosser CJ (2011) Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer 11:233-238.
50. Vande Voorde J, Gago F, Vrancken K, Liekens S, and Balzarini J (2012) Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues. Biochem J 445:113-123.
51. Yang H, Qu L, Ma H, Chen L, Liu W, Liu C, Meng L, Wu J, and Shou C (2010) Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol 10:132-139.
52. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, and Sugimoto N et al. (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993-1001.
53. Zhang Y, Parker WB, Sorscher EJ, and Ealick SE (2005) PNP anticancer gene therapy. Curr Top Med Chem 5:1259-1274.